UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 16, 2017
ALTIMMUNE, INC.
(Exact name of registrant as specified in its Charter)
| Delaware | 001-32587 | 20-2726770 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 19 Firstfield Road, Suite 200 Gaithersburg, Maryland |
20878 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number including area code: (240) 654-1450
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) ) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) ) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 | Other Events |
On May 16, 2017, Altimmune, Inc. (the “Company”) announced the appointment of Sybil Tasker, M.D., FACP, FIDSA, the Company’s Senior Vice President of Clinical Research and Development, as the Company’s Chief Medical Officer. A copy of the Company’s press release announcing Dr. Tasker’s appointment as Chief Medical Officer is attached hereto as Exhibit 99.1.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. |
Description of Exhibit | |
| 99.1 |
Press release dated May 16, 2017 | |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: May 16, 2017 | ALTTIMUNE INC. | |||||
| By: | /s/ William Enright | |||||
| Name: | William Enright | |||||
| Title: | Chief Executive Officer | |||||
3
EXHIBIT INDEX
| Exhibit |
Description of Exhibit | |
| 99.1 |
Press release dated May 16, 2017 | |
4
Exhibit 99.1
Altimmune Promotes Dr. Sybil Tasker to Chief Medical Officer
GAITHERSBURG, MD., May 16, 2017 — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced the promotion of Sybil Tasker, M.D., FACP, FIDSA, to the position of Chief Medical Officer. Dr. Tasker joined the company in April 2016 as Senior Vice President, Clinical Research and Development, with responsibility for overseeing Altimmune’s clinical research and development programs.
Bill Enright, President and Chief Executive Officer of Altimmune, stated, “Dr. Tasker has played a critical role in the advancement of our immunotherapeutic and vaccine product candidates and we are delighted to recognize her contributions to our success during the past year. Her expertise in the treatment of infectious diseases and the clinical evaluation of novel vaccine candidates will be invaluable as we continue our NasoVAX™ influenza vaccine, NasoShield™ and Sparvax-L™ anthrax vaccines and HepTcell™ chronic hepatitis B immunotherapeutic development programs and advance our Oncosyn™ cancer immunotherapeutics into human clinical studies.”
Before joining Altimmune, Dr. Tasker was Senior Director of Clinical Development at Genocea Biosciences where she led the GEN-003 therapeutic vaccine program. Previously, Dr. Tasker had positions of increasing responsibility in infectious-disease product development strategy at two global CROs and was the senior U.S. Navy physician and technical advisor to the Department of Defense on a wide variety of infectious-disease policy issues, including HIV, tropical disease, vaccination, infection control, bioterrorism and pandemic preparedness. Dr. Tasker is board-certified in internal medicine and infectious diseases and received an A.B. in biochemistry from Princeton University, a Master of Public Health degree from Johns Hopkins University and an M.D. from Columbia University.
About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease and on the development of two next-generation anthrax vaccines that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines. The company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines.
Forward-Looking Statement
Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the prospects for commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Altimmune, Inc. (the “Company”) may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: realizing the benefits of the merger between Altimmune, Inc. and PharmAthene, Inc.; clinical trials and the commercialization of proposed product candidates (such as marketing, regulatory, product liability, supply, competition, dependence on third parties and other risks); the regulatory approval process; dependence on intellectual property; the Company’s BARDA contract and other government programs, reimbursement and regulation; and the lack of financial resources and access to capital to fund proposed operations. Further information on the factors and risks that could affect the Company’s business, financial conditions and results of operations are contained in the Company’s filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.
Altimmune Contacts
Bill Enright
President and CEO
Phone: 240-654-1450
Email: enright@altimmune.com
Matthew Duffy
Investor Relations
Phone: 212-915-0685
Email: matthew@lifesciadvisors.com